For instance, in preclinical cancer models, the combination of anti‐PD‐1 therapy with anti‐angiogenic agents targeting the VEGF pathway can reduce the formation of VM and enhance anti‐tumour immunity [117]. This evidence concerns the gene VEGFA and neoplasm.